{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:33:38Z","timestamp":1777131218961,"version":"3.51.4"},"reference-count":4,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clon.2026.104100","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:05:52Z","timestamp":1772294752000},"page":"104100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comment on TWO Versus Five-fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9871-1755","authenticated-orcid":false,"given":"R.","family":"Romrattaphan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1150-1399","authenticated-orcid":false,"given":"P.","family":"Dankulchai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-8861","authenticated-orcid":false,"given":"T.","family":"Prasartseree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0334-2551","authenticated-orcid":false,"given":"W.","family":"Sittiwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Thaweerat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Junlabut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nitipitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104100_bib5","article-title":"Comment on \u2019Two vs Five-fraction Stereotactic Body Radiotherapy","volume":"7","author":"Maji","year":"2026","journal-title":"Clin Oncol (R Coll Radiol). Published online"},{"key":"10.1016\/j.clon.2026.104100_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2025.104029","article-title":"Two Versus Five-Fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial","volume":"51","author":"Romrattaphan","year":"2026","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2026.104100_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.conctc.2017.04.008","article-title":"Design of Phase II Non-inferiority Trials","volume":"7","author":"Jung","year":"2017","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.clon.2026.104100_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial","volume":"181","author":"Ong","year":"2023","journal-title":"Radiother Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T14:34:26Z","timestamp":1777127666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":4,"alternative-id":["S0936655526000713"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104100","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment on TWO Versus Five-fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104100"}}